Gut microbiota metabolizes nabumetone in vitro: Consequences for its bioavailability in vivo in the rodents with altered gut microbiome

Abstract

1. The underlying microbial metabolic activity toward xenobiotics is among the least explored factors contributing to the inter-individual variability in drug response.

2. Here, we analyzed the effect of microbiota on a non-steroidal anti-inflammatory drug nabumetone.

3. First, we cultivated the drug with the selected gut commensal and probiotic bacteria under both aerobic and anaerobic conditions and analyzed its metabolites by high-performance liquid chromatography (HPLC) with UV detection. To analyze the effect of microbiota on nabumetone pharmacokinetics in vivo, we administered a single oral dose of nabumetone to rodents with intentionally altered gut microbiome - either rats treated for three days with the antibiotic imipenem or to germ-free mice. Plasma levels of its main active metabolite 6 methoxy-2-naphthylacetic acid (6-MNA) were analyzed at pre-specified time intervals using HPLC with UV/fluorescence detection.

4. We found that nabumetone is metabolized by bacteria to its non-active metabolites and that this effect is stronger under anaerobic conditions. Although in vivo, none of the pharmacokinetic parameters of 6-MNA was significantly altered, there was a clear trend towards an increase of the AUC, Cmax and t_1/2 in rats with reduced microbiota and germ-free mice.

Keywords:

• Gut microbiome
• pharmacokinetic of nabumetone
• imipenem
• germ-free mice
• bioavailability
• metabolism of drugs

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was supported by The Czech Science Foundation (grant no. 17-09869S) and by Ministry of Health, Czech Republic – conceptual development of research organization (FNOl, 0098892).